Gateway Wealth Partners LLC Buys Shares of 10,200 Puma Biotechnology, Inc. (NASDAQ:PBYI)

Gateway Wealth Partners LLC purchased a new position in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,200 shares of the biopharmaceutical company’s stock, valued at approximately $31,000.

Other large investors also recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in Puma Biotechnology in the 3rd quarter valued at approximately $34,000. Franklin Resources Inc. bought a new stake in shares of Puma Biotechnology in the third quarter worth $41,000. Dynamic Technology Lab Private Ltd acquired a new stake in Puma Biotechnology in the third quarter valued at $44,000. Patriot Financial Group Insurance Agency LLC raised its position in Puma Biotechnology by 72.7% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 8,000 shares during the last quarter. Finally, Royce & Associates LP lifted its holdings in Puma Biotechnology by 71.8% during the 3rd quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company’s stock worth $51,000 after buying an additional 8,427 shares during the period. 61.29% of the stock is currently owned by institutional investors.

Puma Biotechnology Price Performance

PBYI stock opened at $3.04 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The firm has a market cap of $149.23 million, a price-to-earnings ratio of 6.33 and a beta of 1.10. The company’s fifty day simple moving average is $3.08 and its 200 day simple moving average is $2.98. Puma Biotechnology, Inc. has a 12-month low of $2.22 and a 12-month high of $7.73.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.31 by $0.10. The company had revenue of $80.50 million for the quarter, compared to analyst estimates of $71.32 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. During the same quarter in the prior year, the company earned $0.12 EPS. On average, analysts expect that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current year.

Insider Transactions at Puma Biotechnology

In other Puma Biotechnology news, CEO Alan H. Auerbach sold 33,841 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $106,599.15. Following the completion of the sale, the chief executive officer now owns 7,029,674 shares of the company’s stock, valued at approximately $22,143,473.10. This trade represents a 0.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Jeffrey Jerome Ludwig sold 9,437 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total value of $29,726.55. Following the sale, the insider now owns 108,951 shares of the company’s stock, valued at approximately $343,195.65. This represents a 7.97 % decrease in their position. The disclosure for this sale can be found here. Insiders own 23.70% of the company’s stock.

Wall Street Analyst Weigh In

PBYI has been the subject of a number of analyst reports. StockNews.com downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 6th. HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Puma Biotechnology in a report on Monday, December 23rd.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.